Opinion|Videos|May 3, 2024
Overcoming Limitations and Barriers Associated with Treating Pulmonary Arterial Hypertension
Author(s)Ioana Preston, MD
An expert on pulmonary arterial hypertension discusses the limitations of current therapies and the barriers to early diagnosis.
Episodes in this series
Video content above is prompted by the following questions:
- What are the limitations of current pulmonary arterial hypertension (PAH) therapies that primarily focus on symptom management, and how do they impact patient outcomes?
- How does the high disease burden associated with PAH affect patients' quality of life and functional status?
- What are the barriers to early diagnosis and initiation of treatment for PAH, and how do they contribute to poor outcomes?
Related to this article
HYPERION trial data shows a 76% reduction in clinical worsening events among adults recently diagnosed with PAH.
Trending on AJMC
1
Health System Pharmacies Keep Patients on GLP-1 Therapy
2
Peptide Regulation Debate Intensifies After FDA Advisory Panel's Controversial Vote
3
Melatonin Use Linked to Small REM Sleep Reduction in Children
4
Opposing Sides of 340B Debate Converge on Data Clearinghouse, Patient Definition
5